Cost-utility analysis of treatments for advanced non-small cell lung cancer
Lairson, DR., Parikh, R., Cormier, JN., Wenyaw, C., & Du, XL. (2015). Cost-utility analysis of treatments for advanced non-small cell lung cancer. American Journal of Pharmacy Benefits, 7(6), 271-9. http://www.ajpb.com/journals/ajpb/2015/ajpb_novemberdecember2015/cost-utility-analysis-of-treatments-for-advanced-non-small-cell-lung-cancer
Platinum-based chemotherapy may be cost-effective compared with no chemotherapy for the overall elderly population and by age group. However, platinum + targeted therapy was not cost-effective compared with the use of platinum-based therapy alone.